Real-world outcomes of bispecific antibody therapy after chimeric antigen receptor T-cell therapy in follicular lymphoma - PubMed
5 hours ago
- #CAR T-cell Therapy
- #Follicular Lymphoma
- #Bispecific Antibody
- The study investigates real-world outcomes of bispecific antibody therapy after CAR T-cell therapy in follicular lymphoma.
- Key competing interests and funding sources for the authors are disclosed, including ties to pharmaceutical companies like BMS, AbbVie, and Genmab.
- Ethical approvals were obtained with a waiver of consent due to the retrospective nature and minimal risk of the study.